Home > Rheumatology > ACR 2021 > SLE Treatment: What Is New > Sequential rituximab after belimumab does not improve disease control in SLE

Sequential rituximab after belimumab does not improve disease control in SLE

Presented By
Prof. Cynthia Aranow, Feinstein Institutes for Medical Research, NY, USA
Conference
ACR 2021
Trial
Phase 3, BLISS-BELIEVE
A single cycle of rituximab after therapy with belimumab did not improve disease control or remission in patients with active systemic lupus erythematosus (SLE). This was the disappointing main result of the BLISS-BELIEVE study. “Given a potential synergistic mode of action, belimumab and rituximab combination therapy may enhance clinical benefit in SLE patients,” Prof. Cynthia Aranow (Feinstein Institutes for Medical Research, NY, USA) explained [1]. This could be of importance since disease control remains an unmet need in SLE. The objective of the double-blind, placebo-controlled, 104-week, phase 3 study BLISS-BELIEVE (NCT03312907) was to assess the efficacy and safety of sequential therapy with belimumab followed by a single rituximab cycle in patients with SLE. Thus, patients with active SLE received subcutaneous belimumab once weekly for 52 weeks and w...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on